PharmaTalkRadio

In this panel, moderated by Dr Axel Hoos, GSK, individuals from large pharma and biotech business development leads discuss decision-making when it comes to partnering and collaborations in today’s IO environment. What is the current nature and types of partnerships being done in IO?Is dealmaking and partnerships evolving due to the need for IO combinations? How so? What is the balance between in...

This panel, moderated by Dr Priti Hegde, Genentech, discusses the following: How can biomarkers act as a tool for understanding the biology at a level that is sufficient for making decisions around combinations? What are the potential biomarkers that can help predict if a patient will respond to combinations? Once a biomarker is identified in terms of biology, been measured and the technology plat...

In this podcast, Dr Gregory Goldmacher, Executive Director, Translational Biomarkers and Head of Clinical Imaging, Merck Research Labs along with Dr Matthew Silva, Executive Vice President, Scientific Applications, Invicro discuss innovations in IO imaging.   Together, Dr Goldmacher and Dr Silva address: The evolution of treatment response criteria in immuno-oncologyNovel Tracers: Monitoring tumor...

The 2nd annual Drug Delivery West (DDW) Summit provides a west coast venue for biotech, pharma and drug delivery companies to address scientific and business solutions for the best routes of delivery across different therapeutic areas with an emphasis on emerging technologies and to prepare for the future of R&D and clinical care. This podcast discusses who will be presenting and the topics co...

Modernizing Clinical Trials with IQVIA's Dr Cynthia Verst Host: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm:Disrupting Clinical Trials Guest: Dr Cynthia Verst, President, Design and Delivery Innovation for the Research & Development Solutions organization at IQVIA

In this podcast, Valerie Bowling, Executive Director of the Conference Forum, interviews Dr Laura Esserman, breast cancer surgeon and researcher at the University of California, San Francisco. Dr Esserman shares her thoughts on how we can move towards uniting care and clinical research and the future of how medicine should be practiced.

This discussion was presented at the inaugural Drug Delivery West conference in 2018. One of the key challenges in global health is ensuring safe and effective delivery of life saving interventions to remote and non-clinical settings. The Bill & Melinda Gates Foundation invests in technologies, which will help achieve this goal. Learn about an RFP they are launching to indentify new ideas for...

This panel, presented at the inaugural Drug Delivery West conference in 2018, provides patient perspectives on what they want from drug delivery technologies. These case examples provide insight that every technology can benefit from and lessons learned through our patient representatives. Co-Moderators: Valerie Bowling, Patient Advocate and Executive Director, Drug Delivery West Sudeshna Dutta Ra...

In this discussion, CRAACO co-chair, Katherine Vandebelt, Chief Ecosystem Officer, Reify Health, Inc, and Alison Bateman-House, PhD, MPH, MA, Assistant Professor Division of Medical Ethics, NYU Langone Health, consider what lines are being drawn in the integration of clinical care and clinical research. More specifically: Research and care or treatment are separate spheres in the regulatory and et...

In this discussion, stakeholders from medical practices, hospitals, service providers, and patient advocacy discuss how medical practices can offer clinical trials to patients. Including: Infrastructure and supportHow to establish physician championsHow to influence leadership supportContacting patients Moderated by: Jennifer Byrne, Founder, Greater Gift Initative Panelists: Judy Hung, MD, Directo...

Murray Abramson, MD, VP Clinical Operations, Biogen and Jeff James, CEO, Wilmington Health, discuss the blockers and enablers to making clinical research a care option. Discuss includes: What are the blockers or conflicts (laws, culture, behaviors, etc) that prevent clinical research from becoming a care option? What is the difference between a movement and an initiative - how should be think abou...

Jonathan Jackson, PhD, Director CARE Research Center, Massachusetts General Hospital, and Jim Kremidas, Executive Director, Association of Clinical Research Professionals (ACRP) sit down for a frank discussion on the benefits of offering clinical research in underserved communities. Many communities, whether affected by race, ethnicity, or socioeconomic lines, are underrepresented in clinical rese...

Chief Medical Officer Summit co-chair, Jim Roach, and prominent biotech investor, Elizabeth Stoner, sit down for a fireside chat to discuss what investors are seeking when investing in a biotech company, particularly traits of a Chief Medical Officer. Stoner shares her insights on longevity, key qualities of an effective CMO, and how her perspective as a biotech veteran and former director of clin...

Mark Currie, President of R&D at Ironwood Pharmaceuticals, shares his amazing journey driving a product from establishing the foundation for the discovery of linaclotide by Ironwood scientists and leading every aspect of linaclotide's development and regulatory review. He shares his thought processes, pressure points, and lessons learned in leading the R&D team to get a product successfull...

In this podcast, Dr Alison Bateman-House, Assistant Professor, Division of Medical Ethics at NYU Langone Health, discusses the debate of compassionate use and the right to try. It dives into the implications, both positive and negative, of opening up that door.

In this podcast, Raju Joshi, Managing Partner at Clinical Partners Group and Dr Zain Kassam, CSO at Finch Therapeutics, discuss how CMO's can more effectively communicate with CEO's, CSO's, and Clinical Operations executives in order to prove a comprehensive summary of the science and business aspects of the company. You can join us at the 7th annual Chief Medical Officer Summit happening April 4-...

Mary Stober Murray, Associate Director, Diversity and Patient Engagement for BMS, discusses applying quality systems framework (structure, processes, outcomes) to patient engagement initiatives to help create clinical development deliverables that meet industry goals while aligning with patients needs. Mary Stober Murry will be joining the 6th annual Patients as Partners US program on March 11-12...

In this podcast, we were joined by Mr Charles Graeber, award-winning journalist and author who recently published The Breakthrough: Immunotherapy and the Race to Cure Cancer along with Dr James Gulley, Head of the Immunotherapy Section and Director of the Medical Oncology Service at the Center for Cancer Research within the National Cancer Institute. Together Mr Graeber and Dr Gulley delved into t...

This podcast features a panel previously recorded at the 5th annual Patients as Partners US program on Engaging Patients By Giving Them their Data. The panel, moderated by David Leventhal, Director of Clinical Innovation for Pfizer, discussed: • What information and data do patients want during a clinical trial? • What initiatives is pharma currently doing to support this? • What impact will it ha...

Les Jordan, Working Group Member and Cindy Geoghegan, Team Lead for CTTI, the Clinical Trials Transformation Initiative, share findings from a multi-stakeholder project undertaken by the Clinical Trials Transformation Initiative to better understand patient perspectives on mobile technologies in clinical trials. The survey, conducted amongst 100 patients across multiple therapeutic areas, evaluate...

Dr Marilyn Metcalf, Head of the Center of Innovation for GSK, at the 5th annual Patients as Partners 2018 program. Dr Metcalf shares how GSK implemented pivotal end-to-end engagement initiatives at different stages of development. Dr Metcalf walked the audience through some examples of the engagement initiatives supported by: • Creation of a framework and toolkit that builds on existing infrastruc...

To prevent ticking off a box and to ensure that patient involvement is systemic and sustainable, we have to move into patient-centricity 2.0. What does this mean and how is this done so we can turn the patient voice into value, impact, and benefit? This session presented at the 2nd annual Patients as Partners EU meeting, which took place January 2018 in London, demonstrates best practices from Hof...

What would have to change to make a patient-centric healthcare system a reality? How can this be achieved, given the huge resistance to change built into current systems? In this session, Alastair Kent, Director of Genetic Alliance UK, addresses: New opportunities to interveneDemographic changeConstrained funding right across EuropeThe introduction of Expert Reference NetworksHow we can work throu...

This 8 minute podcast summarizes what you can expect at the 6th annual Patients as Partners US conference. This is the only event that truly demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. The conference takes place March 11-12, 2019 at the Wyndham Philadelphia Historic District, Philadelphia, PA. The p...

Medical research charities in the UK have been successfully integrating patient insight into their activities for over 10 years. In this session presented at the 2nd annual Patients as Partners Europe in January 2018, Claire Nolan, Research Involvement Manager, Parkinson's UK, and Chris MacDonald, Research Involvement Manager, Arthritis Research UK, explore a shift in attitiude towards pharmaceuti...